Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin induction chemotherapy followed by gemcitabine concurrent with IMRT for locally recurrent nasopharyngeal carcinoma
ChiCTR-ONC-12002613Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Oct 2016; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-ONC-12002613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002613.